Hubei Jumpcan Pharmaceutical Co Ltd - Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has an Asset Resilience Ratio of 48.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hubei Jumpcan Pharmaceutical Co Ltd (600566) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Hubei Jumpcan Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hubei Jumpcan Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥8.65 Billion | 48.48% |
| Total Liquid Assets | CN¥8.65 Billion | 48.48% |
Asset Resilience Insights
- Very High Liquidity: Hubei Jumpcan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 48.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Jumpcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Jumpcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.40% | CN¥6.27 Billion ≈ $916.85 Million |
CN¥17.70 Billion ≈ $2.59 Billion |
+7.44pp |
| 2024-12-31 | 27.96% | CN¥5.16 Billion ≈ $755.21 Million |
CN¥18.46 Billion ≈ $2.70 Billion |
+10.44pp |
| 2023-12-31 | 17.52% | CN¥3.18 Billion ≈ $465.08 Million |
CN¥18.14 Billion ≈ $2.65 Billion |
-2.81pp |
| 2022-12-31 | 20.32% | CN¥3.04 Billion ≈ $445.51 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+6.51pp |
| 2021-12-31 | 13.81% | CN¥1.68 Billion ≈ $245.11 Million |
CN¥12.13 Billion ≈ $1.78 Billion |
+1.84pp |
| 2020-12-31 | 11.96% | CN¥1.26 Billion ≈ $184.08 Million |
CN¥10.52 Billion ≈ $1.54 Billion |
+9.77pp |
| 2019-12-31 | 2.19% | CN¥190.00 Million ≈ $27.80 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.50pp |
| 2018-12-31 | 3.69% | CN¥288.00 Million ≈ $42.14 Million |
CN¥7.80 Billion ≈ $1.14 Billion |
-6.39pp |
| 2017-12-31 | 10.09% | CN¥672.00 Million ≈ $98.33 Million |
CN¥6.66 Billion ≈ $974.94 Million |
+5.88pp |
| 2016-12-31 | 4.21% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.99 Billion ≈ $729.84 Million |
+0.58pp |
| 2015-12-31 | 3.63% | CN¥130.00 Million ≈ $19.02 Million |
CN¥3.59 Billion ≈ $524.66 Million |
-4.71pp |
| 2014-12-31 | 8.34% | CN¥280.00 Million ≈ $40.97 Million |
CN¥3.36 Billion ≈ $491.34 Million |
+8.29pp |
| 2006-12-31 | 0.05% | CN¥400.00K ≈ $58.53K |
CN¥786.51 Million ≈ $115.09 Million |
-5.83pp |
| 2003-12-31 | 5.88% | CN¥38.22 Million ≈ $5.59 Million |
CN¥650.39 Million ≈ $95.17 Million |
-1.38pp |
| 2002-12-31 | 7.26% | CN¥44.08 Million ≈ $6.45 Million |
CN¥607.22 Million ≈ $88.85 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more